The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[5-methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]] which results in decreased susceptibility to Daunorubicin; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of ABCB1 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of ABCB1 mRNA; [Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Sodium Azide co-treated with Iodoacetates] inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]; ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]; ABCB1 mutant form promotes the reaction [Magnetite Nanoparticles results in increased susceptibility to Daunorubicin]; Amiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; aurapten promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; Cyclosporine inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Daunorubicin]; Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]; Daunorubicin promotes the reaction [Magnetite Nanoparticles results in decreased expression of ABCB1 protein]; desethylamiodarone inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]]; Magnetite Nanoparticles promotes the reaction [ABCB1 mutant form results in increased susceptibility to Daunorubicin]; Magnetite Nanoparticles promotes the reaction [Daunorubicin promotes the reaction [ABCB1 mutant form results in decreased expression of ABCB1 protein]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 mRNA]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of ABCB1 protein]; Mitotane inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; nobiletin promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]; Sesquiterpenes analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Daunorubicin]; valspodar inhibits the reaction [ABCB1 protein results in increased export of Daunorubicin]; Verapamil inhibits the reaction [[5-methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [[Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin] ABCB1A affects the susceptibility to Daunorubicin Daunorubicin inhibits the reaction [ABCB1 results in increased transport of estradiol-17 beta-glucuronide] ABCB1 protein results in increased export of Daunorubicin; ABCB1A protein results in increased export of Daunorubicin ABCB1 protein affects the transport of Daunorubicin Daunorubicin results in decreased expression of ABCB1 mRNA; Daunorubicin results in decreased expression of ABCB1 protein ABCB1 protein results in decreased uptake of Daunorubicin ABCB1 affects the susceptibility to Daunorubicin; ABCB1 protein affects the susceptibility to Daunorubicin
ABCC1 protein affects the export of Daunorubicin ABCC1 results in decreased susceptibility to Daunorubicin ABCC1 protein results in increased secretion of Daunorubicin ABCC1 affects the susceptibility to Daunorubicin; ABCC1 protein affects the susceptibility to Daunorubicin Benzbromarone inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin]; Folic Acid deficiency inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; homocamptothecin inhibits the reaction [ABCC1 protein results in increased secretion of Daunorubicin]; PAK 104P inhibits the reaction [ABCC1 protein affects the export of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein affects the export of Daunorubicin] ABCC1 protein results in decreased susceptibility to Daunorubicin; ABCC1 results in decreased susceptibility to Daunorubicin Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]
ABCC2 affects the susceptibility to Daunorubicin [5-methoxypsoralen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin; [Methoxsalen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin; Indomethacin inhibits the reaction [[5-methoxypsoralen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Indomethacin inhibits the reaction [[Methoxsalen results in decreased activity of ABCC2 protein] which results in decreased export of and results in increased abundance of Daunorubicin]
AKR1A1 protein results in increased reduction of Daunorubicin AKR1A1 SNP affects the metabolism of Daunorubicin [AKR1A1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol
AKR1B10 protein results in decreased susceptibility to Daunorubicin AKR1B10 protein results in increased reduction of Daunorubicin [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; pirinixic acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]
AKR1C3 protein results in increased metabolism of Daunorubicin; AKR1C3 results in increased metabolism of Daunorubicin AKR1C3 protein results in decreased susceptibility to Daunorubicin [AKR1C3 protein results in increased metabolism of Daunorubicin] which results in increased abundance of daunorubicinol; [Tretinoin results in decreased activity of AKR1C3 protein] which results in increased susceptibility to Daunorubicin; dinaciclib inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; NVP-BKM120 inhibits the reaction [AKR1C3 protein results in increased reduction of and results in decreased susceptibility to Daunorubicin]; Tretinoin inhibits the reaction [[AKR1C3 protein results in increased metabolism of Daunorubicin] which results in increased abundance of daunorubicinol]; Tretinoin inhibits the reaction [AKR1C3 protein results in increased metabolism of Daunorubicin]
[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA; [bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of BAX protein; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX mRNA; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of BAX protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of BAX mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of BAX protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX protein; bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of BAX protein]; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of BAX mRNA]; Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of BAX mRNA] Daunorubicin results in increased expression of BAX mRNA
[Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BCL2 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in decreased expression of BCL2 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in decreased expression of BCL2 protein]; bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]; bromotetrandrine promotes the reaction [Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [bromotetrandrine promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA]]; Magnetite Nanoparticles promotes the reaction [Daunorubicin results in decreased expression of BCL2 mRNA] Daunorubicin affects the expression of BCL2 mRNA BCL2 results in decreased susceptibility to Daunorubicin
[bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BIRC5 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BIRC5 protein; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in decreased expression of BIRC5 protein Daunorubicin results in increased expression of BIRC5 mRNA; Daunorubicin results in increased expression of BIRC5 protein Daunorubicin affects the expression of BIRC5 mRNA
[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA; [bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 protein; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 protein; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with bromotetrandrine] results in increased expression of CASP3 protein; [Daunorubicin co-treated with Magnetite Nanoparticles] results in increased expression of CASP3 mRNA; [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Magnetite Nanoparticles co-treated with Daunorubicin] promotes the reaction [bromotetrandrine results in increased expression of CASP3 protein]; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA; [Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 protein; bromotetrandrine promotes the reaction [[ferric oxide co-treated with ferrous oxide co-treated with Daunorubicin] results in increased expression of CASP3 protein]; bromotetrandrine promotes the reaction [[Magnetite Nanoparticles co-treated with Daunorubicin] results in increased expression of CASP3 mRNA]; Magnetite Nanoparticles promotes the reaction [[bromotetrandrine co-treated with Daunorubicin] results in increased expression of CASP3 mRNA] Daunorubicin affects the expression of CASP3 mRNA Daunorubicin results in increased activity of CASP3 protein
CBR1 protein results in increased metabolism of Daunorubicin; CBR1 results in increased metabolism of Daunorubicin CBR1 protein results in increased reduction of Daunorubicin CBR1 gene SNP results in decreased metabolism of Daunorubicin 8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; [[Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin] which results in decreased chemical synthesis of daunorubicinol; [CBR1 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; [CBR1 results in increased metabolism of Daunorubicin] which results in increased chemical synthesis of daunorubicinol; [Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin; [S-Nitrosoglutathione binds to CBR1 protein] inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; isoxanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; xanthohumol inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]
CBR3 gene SNP affects the susceptibility to Daunorubicin CBR3 protein affects the metabolism of Daunorubicin; CBR3 protein alternative form affects the metabolism of Daunorubicin
Daunorubicin results in increased expression of CDKN1A; Daunorubicin results in increased expression of CDKN1A mRNA; Daunorubicin results in increased expression of CDKN1A protein
Daunorubicin results in increased expression of EDN1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDN1 protein]
Daunorubicin results in increased expression of EDNRA protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDNRA protein]
Daunorubicin results in increased expression of EDNRB protein telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein]
Daunorubicin results in increased phosphorylation of EIF4EBP1 protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein]
Daunorubicin results in increased expression of ICAM1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of ICAM1 protein]
Daunorubicin results in increased expression of MT1A mRNA; Daunorubicin results in increased expression of MT1A protein Zinc promotes the reaction [Daunorubicin results in increased expression of MT1A mRNA]; Zinc promotes the reaction [Daunorubicin results in increased expression of MT1A protein]
Daunorubicin results in increased phosphorylation of MTOR protein Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein]
Daunorubicin results in increased expression of NCF2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF2 protein]
Daunorubicin results in increased expression of NOX4 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NOX4 protein]
Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]; Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin] NPC1 affects the susceptibility to Daunorubicin
Daunorubicin results in decreased expression of NPPB mRNA; Daunorubicin results in decreased expression of NPPB protein Daunorubicin results in increased expression of NPPB mRNA Daunorubicin results in increased expression of NPPB protein
Daunorubicin results in increased activity of NQO1 protein Daunorubicin results in decreased expression of NQO1 mRNA; Daunorubicin results in decreased expression of NQO1 protein
Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] Daunorubicin results in decreased activity of NR1H4 protein Daunorubicin results in increased activity of NR1H4 protein
[Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein Daunorubicin affects the expression of PARP1 mRNA Daunorubicin results in increased cleavage of PARP1 protein
telmisartan promotes the reaction [Daunorubicin results in increased expression of PPARG protein] Daunorubicin results in decreased activity of PPARG protein
Daunorubicin results in increased expression of PTGS2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of PTGS2 protein]
Daunorubicin results in increased phosphorylation of RPS6KB1 protein Daunorubicin results in decreased expression of RPS6KB1 mRNA Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein]
Razoxane inhibits the reaction [Daunorubicin results in decreased expression of RYR2 mRNA] Daunorubicin results in increased expression of RYR2 protein
Daunorubicin results in decreased expression of SERPINE1 mRNA; Daunorubicin results in decreased expression of SERPINE1 protein Daunorubicin results in decreased secretion of SERPINE1 protein [Daunorubicin results in increased abundance of Ceramides] which results in decreased secretion of SERPINE1 protein; fumonisin B1 inhibits the reaction [Daunorubicin results in decreased expression of SERPINE1 protein]
Daunorubicin results in increased expression of SMPD3 mRNA; Daunorubicin results in increased expression of SMPD3 protein SMPD3 results in increased susceptibility to Daunorubicin
Daunorubicin results in decreased secretion of SOD2 protein nebivolol inhibits the reaction [Daunorubicin results in decreased secretion of SOD2 protein]
[Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Daunorubicin co-treated with TNFSF10 protein] results in increased expression of BID protein; Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10A mRNA]; Daunorubicin promotes the reaction [TNFSF10 results in increased expression of TNFRSF10B mRNA]
nebivolol inhibits the reaction [Daunorubicin results in increased expression of TNNT2 protein] Daunorubicin results in increased secretion of TNNT2 protein
[Daunorubicin co-treated with Magnetite Nanoparticles] results in increased activity of TP53 protein; Daunorubicin results in increased phosphorylation of and results in increased expression of TP53 protein Daunorubicin results in increased activity of TP53 protein Daunorubicin results in increased expression of TP53 mRNA
Daunorubicin results in increased expression of VCAM1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of VCAM1 protein]
browse the term
